Biocon launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands

Sanofi secures two breakthrough nods in China for rare blood disorders

Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia

Grace and Molecule.one strike multi-year AI pact to break peptide manufacturing bottlenecks

These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes

EMA backs higher-dose Wegovy, clearing path for greater weight loss option in Europe

Eli Lilly’s retatrutide delivers breakthrough results in obesity & knee osteoarthritis trial

Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints

Biocon to merge Biocon Biologics in $5.5 billion deal

Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million

Eli Lilly pledges $40 million to Indiana University to expand clinical trials

The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy

Gan & Lee Pharma launches Phase 3 trial of once-monthly weight-loss jab

Novo Nordisk fast-tracks higher-dose obesity drug to FDA

The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway

Zydus receives FDA’s tentative approval for Empagliflozin and Linagliptin tablets